Does glucokinase activator PSN-GK1 display enhanced antihyperglycaemic and insulinotropic actions?
PSN-GK1 was potently antihyperglycaemic through its effects on insulin release and hepatic glucose metabolism. It is one of the most potent GKAs described in the literature and is active in diabetic animal models where GKAs have not been reported to show efficacy to date. Ongoing human trials are investigating the potential of this novel therapeutic approach.
Therefore, recompartmentalization of psoriasis-associated T-cell subsets between PB and lesional skin was not induced in this study as a therapeutic principle. Consequently, recompartmentalization of T-cell subsets does not seem an obligatory event in order to achieve good clinical response.